host

(redirected from Immunocompromised host)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.

host

(Multitude), noun a many, a mass of, an abundance of, army, array, assembly, body, cloud, cluster, company, congregation, crowd, crush, flood, galaxy, group, herd, horde, jam, large amount, litter, nest, no end of, numbers, pack, panoply, school, scores, slew, storm

host

(Owner), noun barkeeper, bartender, hostess, hotel keeper, innkeeper, inviter, owner, owner of an estabbishment, proprietor, restaurant owner, saloon keeper, serving liquor, tavern keeper
Associated concepts: host liability statute
See also: body, collection, mass, plurality, quantity
References in periodicals archive ?
The preceding measles rash may be subtle or absent in an immunocompromised host.
Immunocompromised hosts are particularly at risk of PV-B19 infection, including patients with congenital or acquired immune deficiency, acquired immunodeficiency syndrome (AIDS) and cancer, and in transplant patients on immunosuppressive treatment.
These findings indicate that E bieneusi may disseminate and represent a common cause of peritonitis of unknown origin in the immunocompromised host.
microti infection in highly immunocompromised hosts (8,10).
The emergence of resistant organisms as a cause of serious infection in the immunocompromised host requires a reexamination of our infection control practices.
To the Editor: Extrapulmonary involvement of tuberculosis increases with the rise of the incidence of immunocompromised host, especially in acquired immunodeficiency syndrome, and it can occur even in immunocompetent patients.
Trichodysplasia spinulosa newly described folliculocentric viral infection in an immunocompromised host.
2) Such a designation clarifies that these infections are not rare illnesses restricted to esoteric corners of medical practice, but rather, relatively common infections in a previously rare but now routinely encountered organism-the immunocompromised host.
Chanock's laboratory is in the Immunocompromised Host Section, Pediatric Oncology Branch, at the Advanced Technology Center of the National Cancer Institute.
As previously reported, a retrospective review of data from open label clinical trials, presented at the 1996 Symposium on Infections in the Immunocompromised Host, showed an overall response rate to AMPHOTEC of 53 percent in 99 patients with well-documented fungal infections who received a minimum of seven days of treatment.
The case suggests that, even without an identifiable immunocompromised condition, a patient with LYG should be considered an immunocompromised host, and rituximab or other immunosuppressive treatments should be prescribed cautiously; the possibility for rare complications should be recognized.